Summary of Clinical Use

Alemtuzumab is primarily used for the treament of relapsing-remitting multiple sclerosis (RRMS). Based on results from clinical trials, the UK National Institute for Health and Care Excellence (NICE) approved use of this drug for RRMS in May 2014. In November 2014, the US FDA approved alemtuzumab for RRMS. A list of clinical trials for this drug in MS patients is available using this link to ClinicalTrials.gov. Alemtuzumab can also be used in B-cell chronic lymphocytic leukemia (CLL) therapy and in transplant indications, but access for these indications is controlled through a patient access programme (in the UK). In other jurisdictions use for this indication has been discontinued. Results from Phase 3 trial NCT00548405, suggest that treating RRMS patients with alemtuzumab earlier can actually improve preexisiting disability, rather than just slowing disease progression (with caveats around risk-benefit, and the serious side-effects of alemtuzumab therapy; side-effects such as infusion associated reactions, infections, and development of other autoimmune diseases) [3].

Mechanism Of Action and Pharmacodynamic Effects

Hypothesised to act via the activation of antibody-dependent cell-mediated cytotoxicity.

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)